Fludarabine: all 769 studies that test it
Page 7 of 8. Open to participants first (148), then studies with results posted, then the rest; newest registration first within each.
- CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor TransplantCompletedNCT01049854Phase 2
- Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic SclerosisWithdrawnNCT01047072Phase 2
- Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in RemissionCompletedNCT01020734Phase 2
- Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk LeukemiaCompletedNCT01020539Phase 1
- Infusion of Expanded Cord Blood T CellsWithdrawnNCT00972101Phase 1
- Sickle Cell Disease Conditioning for Bone Marrow TransplantCompletedNCT00968162Phase 1
- Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic DiseaseStatus unknownNCT00959231Phase 2
- Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell LymphomaStatus unknownNCT00958854Phase 2
- Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic MalignanciesTerminatedNCT00943293Phase 1
- T-cell Based Immunotherapy for of MelanomaCompletedNCT00937625Phase 1/2
- GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the ElderlyCompletedNCT00925873Phase 3
- Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and ThymoglobulinTerminatedNCT00915811Phase 2
- Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin LymphomaStatus unknownNCT00907036Phase 2
- Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced SarcomaActive, not recruitingNCT00902044Phase 1
- Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.CompletedNCT00890500Phase 1
- Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AMLStatus unknownNCT00887042Phase 1/2
- Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS)CompletedNCT00885833Phase 1/2
- Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)Status unknownNCT00882323Phase 2
- Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)TerminatedNCT00881556Early Phase 1
- Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell TransplantCompletedNCT00880815Phase 1
- Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To TreatmentWithdrawnNCT00845104Phase 2
- Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)Status unknownNCT00815568Phase 2
- CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7CompletedNCT00812669Phase 2
- Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological CancerCompletedNCT00806767Phase 2
- Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to TreatmentCompletedNCT00802568Phase 2
- Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to TreatmentTerminatedNCT00800150Phase 1
- Haploidentical Stem Cell Transplantation in NeuroblastomaStatus unknownNCT00790413Early Phase 1
- FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00769522Phase 3
- Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT00750126Phase 2
- Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLLCompletedNCT00738829Phase 1/2
- Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)Status unknownNCT00737685Phase 2
- Fludara (Oral) Phase II Study for Indolent LymphomaCompletedNCT00688883Phase 2
- Total Marrow Irradiation for Refractory Acute LeukemiaCompletedNCT00686556Phase 1
- Allogeneic Transplantation for Pediatric Leukemias With Unrelated DonorsStatus unknownNCT00679536Phase 1/2
- Nonmyeloablative Allo SCT for the Treatment of Hematologic DisordersCompletedNCT00636909Phase 2
- Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological CancerCompletedNCT00627666Phase 2
- A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate CancerStatus unknownNCT00625430Phase 1
- Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic LeukemiaTerminatedNCT00612612Phase 1
- Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic LymphomaCompletedNCT00608374Phase 3
- Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHLWithdrawnNCT00577161Phase 3
- Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström MacroglobulinemiaCompletedNCT00566332Phase 3
- A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of ResponseCompletedNCT00565981Phase 2
- Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMPCompletedNCT00564512Phase 3
- Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLLTerminatedNCT00543114Phase 1
- Reduced Intensity AlloSCT in(CML) With Persistent DiseaseTerminatedNCT00531310Phase 2
- Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AMLStatus unknownNCT00529880Phase 2
- HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic LeukemiaTerminatedNCT00524667Phase 2
- Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCTCompletedNCT00516152Phase 2
- Cord Blood Expansion on Mesenchymal Stem CellsCompletedNCT00498316Phase 1
- Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00488709Phase 4
- Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid MalignanciesTerminatedNCT00473551Phase 1
- Stem Cell Transplant in Sickle Cell Disease and ThalassemiaActive, not recruitingNCT00408447Phase 2
- Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)CompletedNCT00402558Phase 1
- Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's LymphomaStatus unknownNCT00397800Phase 1/2
- Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's LymphomaWithdrawnNCT00389506Not applicable
- Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma PatientsStatus unknownNCT00382694Phase 2
- Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic DiseasesTerminatedNCT00376519Phase 1
- Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell TransplantCompletedNCT00376480Phase 1
- Therapy for Chronic Cold Agglutinin DiseaseCompletedNCT00373594Phase 2
- Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid CancerCompletedNCT00346359Phase 2
- A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic MalignanciesCompletedNCT00343798Phase 1
- Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic MelanomaActive, not recruitingNCT00338377Phase 2
- Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic LeukemiaCompletedNCT00337246Phase 2
- Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic MelanomaCompletedNCT00324623Phase 1
- Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV MelanomaCompletedNCT00317759Phase 1
- Dendritic Cell Vaccination During Lymphoid ReconstructionCompletedNCT00313508Phase 1
- Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHLCompletedNCT00311129Phase 2
- Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First RemissionCompletedNCT00305708Phase 1/2
- Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00304018Phase 1
- Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00301951Phase 1
- Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic CancerWithdrawnNCT00301912Phase 2
- Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic CancerCompletedNCT00296023Not applicable
- Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency DiseaseCompletedNCT00295971Phase 1
- Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic CancerCompletedNCT00290641Not applicable
- Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's MacroglobulinemiaCompletedNCT00281983Phase 1/2
- Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic LeukemiaTerminatedNCT00281931Phase 2
- Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic LeukemiaCompletedNCT00276848Phase 3
- Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic LeukemiaCompletedNCT00275054Phase 3
- Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic LeukemiaCompletedNCT00262795Phase 3
- Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic LeukemiaCompletedNCT00262782Phase 3
- Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By SurgeryTerminatedNCT00243009Phase 2
- IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell ImmunodeficiencyCompletedNCT00228852Phase 1/2
- A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or ThrombocytopeniaCompletedNCT00220311Phase 4
- Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic MalignanciesCompletedNCT00208923Phase 2
- German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)CompletedNCT00198991Phase 4
- Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00193466Phase 2
- Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML)CompletedNCT00188136Phase 2
- A Study of Children With Refractory or Relapsed ALLCompletedNCT00187083Phase 3
- Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic AnemiaCompletedNCT00186797Not applicable
- Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHLCompletedNCT00185445Phase 2
- Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell LymphomaTerminatedNCT00183989Phase 2
- Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's LymphomaCompletedNCT00169208Phase 2
- Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich SyndromeCompletedNCT00160355Phase 1
- Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00143065Phase 2
- Randomized Study for Patients With Follicular Lymphoma Needing TreatmentCompletedNCT00140569Phase 3
- Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic MelanomaTerminatedNCT00138229Phase 2
- Chemotherapy Followed by Zevalin for Relapsed Mantle Cell LymphomaCompletedNCT00119730Phase 2
- Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00119340Phase 1/2
- Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00112567Phase 1/2
- Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00110071Phase 1